#USA #Cancer Research #NCCN #Plymouth Meeting, Pennsylvania #Nancy L. Lewis

Dr. Nancy L. Lewis Steps into Role as Chief Scientific Officer at NCCN

The National Comprehensive Cancer Network (NCCN), a prominent alliance of leading cancer centers dedicated to patient care, research, and education, has announced the appointment of Dr. Nancy L. Lewis, MBS, FACP, as its new Chief Scientific Officer (CSO). Dr. Lewis is set to take on her new role in May 2026, succeeding Dr. Crystal S. Denlinger, who previously held the position before becoming the organization’s CEO.

A Seasoned Leader in Cancer Research

Dr. Lewis is a distinguished biomedical researcher specializing in clinical trials for the treatment of various solid tumors and hematologic malignancies. With a robust background in oncology, she has served as a senior clinical program lead at Novartis Pharmaceuticals and has been involved in academic positions at several prestigious cancer centers. Dr. Lewis holds degrees from the Pennsylvania State University, Temple University School of Medicine, and Rutgers University, showcasing her extensive academic achievements. Additionally, she completed her residency at the University of Rochester and pursued a fellowship at the Fox Chase Cancer Center, which is also part of the NCCN network.

Driving Innovation in Cancer Care

This appointment comes at a pivotal moment in cancer research, with significant breakthroughs awaiting further exploration, and challenges still to address. According to Dr. Crystal S. Denlinger, the CEO of NCCN, "Dr. Lewis is the perfect person to oversee our efforts as we strive to foster innovation and discover knowledge that enhances the lives of those affected by cancer". Dr. Lewis is expected to be a vital asset to the NCCN leadership team, working towards improving oncology outcomes globally.

Dr. Lewis has received accolades from leading cancer organizations across the United States, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS). In her capacity as CSO, she will be instrumental in several key programs within NCCN, including the Oncology Research Program and the Clinical Practice Guidelines in Oncology, which are critical resources for medical professionals.

Commitment to Education and Global Initiatives

Additionally, Dr. Lewis will manage the NCCN Biomarkers Compendium, the NCCN Radiation Therapy Compendium, and the NCCN Imaging Appropriate Use Criteria, all of which are crucial components of modern oncological practice. She will also contribute to the NCCN’s continuing medical education programs and global initiatives that shape cancer health policy. "I am thrilled to join the National Comprehensive Cancer Network and contribute to its remarkable legacy of advancing high-quality cancer care," Dr. Lewis stated. She expressed her eagerness to work collaboratively with the exceptional staff at NCCN to tackle emerging challenges and implement innovative solutions that will improve the lives of patients worldwide.

As NCCN continues its commitment to ensuring quality, effective, equitable, and accessible cancer treatment and prevention, the leadership of Dr. Lewis marks an important step forward. The organization aims to enhance the standard of living for individuals facing cancer, ensuring that clinical guidelines such as the NCCN Guidelines remain at the forefront of oncological treatment and patient education.

For more information on NCCN and its commitment to cancer care, visit NCCN.org.